Michelina Cairo, MD
Hematology & Oncology · Houston, TXNPI 1497064448
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by AstraZeneca at 41.2% of the total. Reporting peaked in 2022 at $24,519 and has fallen 89.8% since, to $2,505 in 2025. Among hematology & oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $396.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$25K
- Daiichi Sankyo Inc.$18K
- Gilead$9K
- Novartis$5K
- Sanofi$2K
- Pfizer$2K
- plus $2K from 27 others
Across 707 payments — averaging $4408.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$990K
- AstraZeneca$512K
- Pfizer$433K
- Merck$349K
- Genentech, Inc.$286K
- Novartis$179K
- plus $368K from 8 others
What the payments were for
- Consulting fees$30,26649%
- Speaking & faculty fees$26,47043%
- Travel & lodging$7541%
- Food & beverage$4,4127%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $25,499 |
| Daiichi Sankyo Inc. | 13 | $18,003 |
| Gilead | 17 | $8,626 |
| Novartis | 20 | $4,721 |
| Sanofi | 4 | $1,689 |
| Pfizer | 7 | $1,566 |
| Merck | 9 | $203 |
| Johnson & Johnson | 6 | $142 |
| Stemline Therapeutics Inc. | 5 | $130 |
| Seagen Inc. | 2 | $123 |
| Puma Biotechnology, Inc. | 5 | $115 |
| Jazz Pharmaceuticals Inc. | 2 | $111 |
| Lilly USA, LLC | 2 | $91 |
| Tactile Systems Technology Inc | 4 | $89 |
| Incyte Corporation | 5 | $86 |
| Bayer | 3 | $81 |
| GSK | 3 | $75 |
| Boston Scientific | 2 | $74 |
| AbbVie | 3 | $71 |
| Beigene USA, Inc. | 2 | $55 |
| Tempus AI, Inc | 2 | $52 |
| EMD Serono, Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| AVEO Pharmaceuticals, Inc. | 1 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $29 |
| Array Biopharma Inc | 1 | $27 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Mylan Institutional Inc. | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,928 in reported general payments places this provider in the 90th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $503,734 |
| OrserduElacestrant Hcl | 13 | $306,422 |
| KisqaliRibociclib Succinate | 13 | $184,049 |
| Letrozole | 367 | $8,848 |
| Exemestane | 47 | $8,207 |
| Anastrozole | 186 | $3,902 |
| Tamoxifen Citrate | 152 | $2,808 |
| Gabapentin | 99 | $2,113 |
| Ibandronate Sodium | 16 | $634 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $402 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $306 |
| LoperamideLoperamide Hcl | 12 | $221 |
| Ondansetron Hcl | 17 | $162 |
| Olanzapine | 17 | $111 |
| Alprazolam | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $1,566 | $503,73434 claims |
| Stemline Therapeutics Inc.Orserdu | $130 | $306,42213 claims |
| NovartisKisqali | $4,721 | $184,04913 claims |
| Lilly USA, LLCOlanzapine | $91 | $11117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.